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Periostin is a fasciclin-containing adhesive glycoprotein that facilitates the migration and differentiation of cells that have undergone
epithelial–mesenchymal transformation during embryogenesis and in pathological conditions. Despite the importance of post-transformational
differentiation as a general developmental mechanism, little is known how periostin's embryonic expression is regulated. To help resolve this
deficiency, a 3.9-kb periostin proximal promoter was isolated and shown to drive tissue-specific expression in the neural crest-derived Schwann
cell lineage and in a subpopulation of periostin-expressing cells in the cardiac outflow tract endocardial cushions. In order to identify the enhancer
and associated DNA binding factor(s) responsible, in vitro promoter dissection was undertaken in a Schwannoma line. Ultimately a 304-bp peri
enhancer was identified and shown to be capable of recapitulating 3.9 kb peri-lacZ in vivo spatiotemporal patterns. Further mutational and EMSA
analysis helped identify a minimal 37-bp region that is bound by the YY1 transcription factor. The 37-bp enhancer was subsequently shown to be
essential for in vivo 3.9 kb peri-lacZ promoter activity. Taken together, these studies identify an evolutionary-conserved YY1-binding 37-bp region
within a 304-bp periostin core enhancer that is capable of regulating simultaneous novel tissue-specific periostin expression in the cardiac
outflow-tract cushion mesenchyme and Schwann cell lineages.
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reporter miceIntroduction
Periostin was originally isolated as osteoblast-specific
factor-2 from the mouse osteoblastic cell line MC3T3-E1
(Takeshita et al., 1993). There are five human periostin
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doi:10.1016/j.ydbio.2007.04.041constituting in-frame deletions or insertions, implying alter-
native splicing events (Litvin et al., 2004). The gene is
structurally similar to Fasciclin-I, a Drosophila protein
expressed in the peripheral nervous system (PNS) and specific
central nervous system axonal bundles (McAllister et al., 1992).
Fasciclin-I functions in guidance of migrating cells, cell sorting
and adhesion during insect nervous system morphogenesis
(Takeshita et al., 1993). The fasciclin extracellular domain is
repeated four times in periostin and is evolutionary conserved
from man to bacteria (Kawamoto et al., 1998). There are
thought to be both membrane-associated forms and secreted
forms (Litvin et al., 2005; Kudo et al., 2006). Interestingly,
periostin can support osteoblast attachment and spreading.
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integrins and promote integrin-dependent cell adhesion and
enhance cell motility (Gillan et al., 2002). Recently, periostin
has been shown to preferentially localize in collagen-rich
tissues and can directly interact with collagen Type-I fibrils
(Norris et al. 2007). Periostin is widely expressed in normal
embryonic/adult tissues and is highly expressed in diverse
pathological conditions. Multiple reports have demonstrated
elevated serum levels in tumor samples from neuroblastoma
(Sasaki et al., 2002), elevated expression in head/neck
carcinoma samples (Kudo et al., 2006; Gonzalez et al.,
2003), as a novel component of subepithelial fibrosis in
bronchial asthma (Takayama et al., 2006), in response to
vascular injury (Li et al., 2005), in epithelial ovarian cancer
(Gillan et al., 2002) and in patients with bone metastases from
breast cancer (Sasaki et al., 2004) that had undergone
epithelial–mesenchymal transformation (EMT) and metasta-
sized. Significantly, periostin has been shown to potently
promote post-EMT metastatic growth of colon cancer by
augmenting cell survival via the Akt/PKB pathway (Bao et al.,
2004). It is also thought to be responsible for extracellular
matrix (ECM) deposition following myocardial infarction and
pathological transformation (Stanton et al., 2000). In normal
tissues, periostin is expressed during recruitment and attach-
ment of osteoblast precursors in the fibrous periosteum
(Horiuchi et al., 1999; Oshima et al., 2002; Litvin et al.,
2004), post-EMT valve formation and remodeling (Kruzynska-
Frejtag et al., 2001; Lindsley et al., 2005; Litvin et al., 2005),
cranial suture maturation (Oshima et al., 2002) and during
epithelial–mesenchymal signaling associated with craniofacial
development (Kruzynska-Frejtag et al., 2004). We demon-
strated via targeted deletion that periostin (perilacZ) null mice
are predominantly viable and exhibit dwarfism, incisor enamel
defects and an early-onset periodontal disease-like phenotype
(Rios et al., 2005). Similarly, Kii et al. (2006) showed that
periostin is required for eruption of incisors in mice.
Combined, these mouse knockout data suggest that periostin
may be required in utero for events that manifest themselves in
postnatal life (Rios et al., 2005).
Despite the complex and intriguing correlation of disregu-
lated periostin expression levels in both normal and patholo-
gical transformation conditions, very little is known about how
periostin is transcriptionally controlled. Thus, unraveling the
molecular mechanisms that regulate periostin expression could
prove useful for gaining an understanding of numerous
neoplastic diseases as well as normal bone, craniofacial and
heart homeostasis. During osteoblast differentiation, transcrip-
tion of periostin may be regulated by the bHLH transcription
factor, Twist (Oshima et al., 2002), that is associated with EMT
during tumor progression (Yang et al., 2004). To begin to clarify
the molecular regulation of periostin gene expression, we used
bioinformatics and cross-species comparisons to identify seven
highly conserved regions within the proximal 3900 base pairs of
the periostin promoter. We subsequently cloned the 5′ mouse
3.9-kb periostin promoter and in vivo transgenic reporter
analysis revealed lineage-restricted in utero expression within
only Schwann cells and in a subpopulation of endogenousperiostin-expressing cardiac outflow tract (OFT) endocardial
cushion cells. Using EMSA and serial truncation/internal
deletion luciferase reporter in vitro assays, we demonstrate
that a 37-bp enhancer is necessary and that the ubiquitous Ying
Yang-1 (YY1) zinc finger transcription factor binds this 37-bp
enhancer within a protein complex. In addition to YY1's role as
an initiator of tumorigenesis and inhibitor of important cell-
cycle progression and tumor suppressor genes, there is
mounting evidence that YY1 may also play a regulatory role
in normal biological processes (Gronroos et al., 2004; Gordon et
al., 2005; Wang et al., 2006). Further in vitro site-directed
mutagenesis and in vivo deletion assays revealed that this 37-bp
enhancer is necessary for in vivo Schwann and OFT endocardial
cushion lineage reporter expression.
Both Schwann cell and OFT endocardial cushion mor-
phogenesis are dependent upon neural crest morphogenesis
(Jessen and Mirsky, 2002; Conway et al., 2000). Most
Schwann cells are neural crest derived (Le Douarin et al.,
1991) and undergo a defined series of developmental
transitions that ultimately give rise to mature Schwann
cells (Jessen and Mirsky, 2005). Following migration of a
neural crest subpopulation and subsequent activation of the
Schwann cell differentiation cascade, neural crest cells can
give rise to Schwann cell precursors that then undergo a
series of molecular and morphological changes to generate
immature and finally mature myelinating and non-myelinat-
ing Schwann cells (Jessen and Mirsky, 2005). Similarly, a
subpopulation of the cardiac neural crest lineage migrate
and colonize the distal cardiac OFT endocardial cushions
and then undergo a series of molecular and morphological
changes that ultimately forms the septa between the aorta
and pulmonary artery (Jiang et al., 2000; Conway et al.,
2003). These results represent the identification and initial
characterization of a novel enhancer element that modulates
expression of periostin solely within the post-migratory
OFT endocardial cushions and Schwann cell precursors of
the developing mouse embryo.Materials and methods
Bioinformatics analysis
Paired alignment and visualization of homology between mouse and
human PERIOSTIN promoter sequence was undertaken using zPicture
software (Ovcharenko et al., 2004; Loots and Ovcharenko, 2004). Multiple
alignment of mouse (NC_000069), dog (NC_006607), human (NC_000013)
and rat (NC_005101) periostin promoter sequences was accomplished using
the ClustalW software (Thompson et al., 1994). Single polymorphic
nucleotide analysis of PERIOSTIN upstream sequence revealed the presence
of 2 well supported human SNPs (rs17197936a and rs17197908c; indicated in
Fig. 6A).
Animal model
Periostin (perilacZ) knockin knockout mice generated previously (Rios et al.,
2005) were maintained on a C57BL/6J genetic background and fed powdered
Teklad LM-485 Complete Mouse Diet to alleviate runting. Tissue isolation,
fixation and processing for lacZ staining was carried out as described (Rios
et al., 2005). All animal experimentation was performed in accordance with
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Institutional Animal Care and Use Committee at IUPUI (Study #2707).
Generation of 3.9 kbperi-lacZ reporter mice
To begin to identify the cis-elements and trans-factors necessary and sufficient
for periostin developmental transcriptional activity, we PCR cloned 3.9 kb of the
5′ mouse periostin promoter from a 92-kb 129SvJ mouse ES cell genomic
DNAlibary bacterial artificial chromosome (clone#318a12, Genome System Inc.,
St. Louis, MO) using a high-fidelity Thermal Ace DNA polymerase kit
(Invitrogen, Inc., Carlsbad, CA). Its identity and fidelity were confirmed by 4-
fold coverage sequencing and overlaps NCBI Mus musculus chromosome 3
genomic clone #NT_039240. Primers used were as follows: sense (5′ GCgtcga-
cCTAAGGTGGACAGTGCGGAAGAC-3) and antisense (CctcgagCTT-
CAGCCCTGAGCTCCGTCC-3). The primers were engineered to produce a 5′
SalI site (in lowercase letters) and a 3′ XhoI site (in lowercase letters), which
enabled us to directionally clone the insert in frame into a promoterless IRES-
nuclear localized β-galactosidase expression cassette. The resulting construct was
either introduced as a 3.9-kb promoter that contains the 5′-UTR and promoter
elements of periostin genomic DNA (up to but not including the ATG) or as a 5′
truncated 1.2-kb promoter (following digestion with an internal unique StuI site).
Following pronuclear injection, resultant embryos were transferred into
pseudopregnant C57Bl/6 female oviducts. Resulting F1 mice were screened by
Southern blot, and positive males were bred to wild-type C57Bl/6 female mice.
Two 3.9-kb peri-lacZ and four 1.2-kb peri-lacZ independent lines were produced, and
F2 germline transmission of the transgene was examined by both PCR and lacZ
staining (Fig. 2).
Histological, in situ and immunohistochemical analysis
Microdissected embryos of various ages were either fixed briefly with 4%
paraformaldehyde (PFA), flash frozen directly in OCT mounting media (Sakura
Finetek, Torrance, CA) following 10%, 20%, 30% sucrose protection or directly
stained for lacZ and examined as described (Rios et al., 2005). At least 5
embryos at each developmental stage were assessed for β-galactosidase reporter
activity. Immunodetection of periostin (1:8,000 dilution), α-smooth muscle
actin (1:5,000 dilution, αSMA, Sigma, St. Louis MO) and neurofilament-H
(1:8,000 dilution, Chemicon) were performed as described (Kruzynska-Frejtag
et al., 2004). Unfixed frozen embedded embryos were sectioned (10 μm), fixed
briefly with 4% PFA, stained for lacZ and then washed in saline prior to protein
blocking and incubation with a goat anti-Sox10 antibody (1:75 dilution, Santa
Cruz Biotech, CA) and detection via rabbit anti-goat-FITC secondary antibody
(1:100 dilution, Vector Labs, CA). Both sets of immunoassays were repeated at
least 3 times.
Radioactive in situ hybridization detection of endogenous periostin
expression was performed as previously described (Kruzynska-Frejtag et al.,
2001). Sox10 mRNA expression was detected using a cDNA probe, cloned via
PCR amplification from E12.5 whole embryo cDNA using the following
primers: 5′-TCTGTCTTCACCTGGGCTTTand 3′-ATGTCAGATGGGAACC-
CAGA. The 420-bp Sox10 PCR fragment was cloned into the pCRIITOPO
vector (Invitrogen) and sequenced to verify identity and orientation. Both sense
and antisense 35S-UTP-labeled probes were generated, and specific signal was
only observed when sections were hybridized with the antisense probe (repeated
at least 3 times).
RT4-D6P2T cell line
RT4-D6P2T (RT4) rat Schwannoma cells (a kind gift of Dr. Pragna Patel,
USC) were grown in DMEM (Gibco), supplemented with 10% fetal bovine
serum and 100 U/mL penicillin and 100 μg/mL streptomyosin at 37 °C with 5%
CO2.
In order to characterize the RT4 cells and assess endogenous periostin
expression, both RT4 and NIH3T3 (ATCC) lines were used. Additionally,
newborn extracts (n=3) from wild-type and perilacZ null mice were used for
Western analysis as described (Rios et al., 2005). For analysis, ∼100 μg of cell
lysate and medium (equal amounts for RT4 and NIH3T3) and ∼80 μg newborn
samples were resolved via 12% SDS–PAGE (Bio-Rad). Loading was normal-ized using a monoclonal anti-actin antibody (Sigma) at 1:5,000 dilution and the
relative levels of periostin measured using our affinity-purified anti-periostin
rabbit polyclonal antibody at 1:12,000 dilution (Kruzynska-Frejtag et al., 2004).
For immunohistochemical analysis, cells were grown on glass culture slides
(LabTech, Nalge-Nunc Inc.), fixed briefly with 4% PFA and stained for periostin
and Sox10 as described above (n=3). Anti-S100 staining was accomplished
using the S-100 Immunohistology Kit (cat. IMMH-9, Sigma-Aldrich, St. Louis,
MO). All images were taken using a Zeiss AxioSkop2 Plus.
Luciferase reporter constructs, mutagenesis, transfection and
luminometry
The 3.9-kb proximal periostin promoter was directionally cloned into the
promoterless pGL2-Basic vector (Promega Corp., Madison WI). The sequenced
3.9-kb peri-pGL2 clone was then serially and internally deleted to generate a set
of truncated constructs. In addition, site-directed mutagenesis of three mouse–
human homology sites was accomplished using the GeneTailor Site-Directed
Mutagenesis System in a pSKII Bluescript shuttle vector (Invitrogen Carlsbad,
CA). Following sequencing verification of designed mutations, both a 804-bp
and an internal 304-bp enhancer were excised and ligated into pGL2 vectors for
reporter analysis.
Molar equivalents of each construct and 50 ng of the Renilla control plasmid
(pRL-CMV, Promega) were co-transfected into RT4 cells using the Mirus
TransIt-LT1 lipoamine reagent (Mirus Bio Corp. Madison, WI). Following 48 h
incubation at 37 °C, protein lysates were harvested from transfected cells and
accessed for luciferase activity using the Dual-Luciferase Reporter Assay
System (Promega Corp.) Quantitative luminometry was performed using an
Lmax luminometer (Mol. Devices, Sunnyvale, CA). Each transfection was
performed three separate times in duplicate and each sample was read twice.
Electromobility shift assays (EMSA)
Nuclear extract was isolated from RT4 cells following a modified Dignam
protocol (Dignam et al., 1983) and EMSAs performed as described (McFadden
et al., 2000). Radioactive double-stranded DNA probes were generated from
P32-labeled complimentary single stranded oligos and purified by acrylamide gel
purification. Cold probe was generated from the hybridization of unlabeled
oligos. The sequences for the probes are listed in table below:Site 1 5′-ATAATGAACCATTTCTTTCT-3′
Site 2 5′-TCAGTAATGACTTACATCT-3′
Site 3 5′-ACATCTCTGGGTCAGACTTT-3′
Site 12 5′-TAATGAACCATTTCTTTCTCAGTAATGACTTACATCT-3′
Site 123 5′-TAATGAACCATTTCTTTCTCAGTAATGACTTACATCTCTGGGTCAGACTTT-3′
Non-specific 5′-GCTCCACCGCCATCTCCGTATTA-3′
YY1 control 5′-ATGCCTTGCAAAATGGCGTTACTGCAG-3′
SRF control 5′-ACACAGGATGTCCATATTAGGACATCTGC-3′Pure YY1 protein was generated from both pcDNA3-CMV-YY1 and
pcDNA3-CMV-YY1-His-tagged full-length cDNAvectors using the TnT rabbit
reticulocyte lysate expression system (Promega). Equivalent amounts of both
YY1 and unprogrammed lysate were used in EMSA analysis to assess the ability
of YY1 to bind the Site 123 probe listed above. Western blotting with the YY1-
specific antibody (1:1,000 dilution; Santa Cruz) was used to verify that only
programmed lysate contained YY1.
Generation of Hsp68-804peri-lacZ, Hsp68-304peri-lacZ and
Hsp68-3900−37 bp transient F0 transgenic analysis
Two DNA fragments, corresponding to −2924 to −2119 (804 bp) and
−2509 to −2205 (304 bp) were isolated, blunted via Klenow and ligated into a
minimal promoter-lacZ reporter vector, Hsp68-lacZ (Kothary et al., 1989;
McFadden et al., 2000). The 37-bp enhancer, corresponding to −2373 to −2336
was deleted from the original 3.9-kb 5′-prime UTR and promoter fragment using
the GeneTailor Site-Directed Mutagenesis System, to make the Hsp68-
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the various linearized transgenes (IU School of Medicine Transgenic Core
Facility) and harvested at E12–13 gestational age. Following microdissection
and isolation of limb buds for PCR genotyping, F0 embryos were fixed, stained
for lacZ and paraffin embedded for detailed histological analysis.Results
Bioinformatic analysis
In order to better understand the mechanisms driving
dynamic periostin expression in utero, we made use of
comparative species sequence analysis. Such analysis is based
on the concept that small non-coding sequences conserved
between related species are likely the product of positive
selection and often contain critical transcriptional regulatory
elements. Cross-species comparison indicates that the majority
of evolutionarily conserved domains were present within the
proximal 4 kb of periostin upstream region relative to the
location of the transcriptional start site. This putative periostin
promoter sequence, designated 3.9 kb peri, includes 3866 bp of
the sequence immediately upstream of the transcriptional start
site and 18 bps of non-coding exon 1. Comparative analysis
reveals relatively homogenous distribution of highly conserved
sequence between rat and mouse (86.2% identity). In contrast,
when 3.9 kb peri was aligned with more distantly related species
such as dog and human, seven discrete focal peaks of high
identity are revealed (data not shown). Interestingly, the peaks
in the two non-rodent species were highly similar, both in term
of degree of sequence identity and spatial distribution. As a
number of possible cis-modules were identified within theFig. 1. Developmental expression pattern of 3.9 kb peri-lacZ transgenic reporter: Deve
3.9 kb peri-lacZ expressing β-galactosidase-positive cells using X-gal substrate (n=48)
(arrow in panel A) and continues throughout development as the staining intensity
detected in E11 facial ganglia and facial nerves (C). Robust punctuate 3.9 kb peri-lacZ ex
and fetal dorsal root ganglia and corresponding nerves (arrows in panel I). Note tha
expression is maintained in the left and right sympathetic trunks and ganglia (arrowproximal 4 kb of periostin, we tested their role directly by
generating transgenic mice designed to drive expression of the
β-galactosidase reporter via this conserved 3.9 kb peri region.
Periostin proximal 3.9 kb promoter expression patterns
The 3.9-kb peri sequence was cloned into a nuclear-
localized β-galactosidase reporter vector. The resulting
construct was either introduced as an intact 3.9-kb periostin
promoter or as a 5′ truncated 1.2 kb periostin promoter
(following digestion with a unique internal Stu1 site). The
1.2-kb construct facilitated the in vivo assessment of a
previously identified in vitro Twist binding site at position
−468 bp (Oshima et al., 2002).
Two 3.9 kb peri-lacZ and four 1.2 kb peri-lacZ independent
permanent mice lines were produced and their respective β-
galactosidase reporter expression patterns examined. Transgenic
analysis revealed that the 1.2-kb peri-lacZ promoter (all four lines)
was not capable of driving any lacZ reporter expression in vivo
at any stage during embryonic and extraembryonic development
(E8-newborn stages examined; not shown). In contrast,
spatiotemporal analysis of two independent 3.9 kb peri-lacZ
lines revealed that lacZ reporter expression is present throughout
the PNS, enteric nervous system and within a subpopulation of
cardiac OFTendocardial cushion mesenchymal cells. In contrast
to the relatively widespread endogenous periostin embryonic
gene expression (Kruzynska-Frejtag et al., 2001; Kruzynska-
Frejtag et al., 2004; Lindsley et al., 2005; Rios et al., 2005),
3.9 kb peri-lacZ expression is only present in restricted subpopula-
tions. As both 3.9 kb peri-lacZ lines exhibited similar reproducible
expression patterns and were both found in normal Mendelianlopmental series of mouse embryos E10–18 and adult organs stained to detect
. (A) Note expression begins at ∼E10 in the trunk PNS adjacent to the forelimb
progressively increases (B–H). Weak 3.9 kb peri-lacZ expression can initially be
pression is also present in E15 midgut enteric nervous system (arrow in panel H)
t 3.9 kb peri-lacZ expression is absent from the CNS. Postnatally, 3.9 kb peri-lacZ
s in panel J) and in the network of adult enteric ganglia (K).
Fig. 2. The 3.9 kb peri-lacZ reporter is expressed in Schwann lineage. (A) Endogenous periostin protein is expressed in many E14 tissues and organs, particularly in
periosteum and around dorsal root ganglia (arrow in panel A). Note that while periostin is expressed in many tissues, it is absent from the neural tube (nt). (B) In
newborns, the dorsal root ganglia, its sheath and the nerve emanating from the ganglia are intensely labeled. (C–E) Sections of lacZ stained 3.9 kb peri-lacZ transgenic-
positive E14 embryo reveals β-galactosidase-positive cells throughout dorsal root ganglia (drg) and along nerve tracks (arrow in panel C). Double labeling with α-
smooth muscle actin (SMA) and neurofilament-H (NF) antibodies revealed that the lacZ-positive cells are neither smooth muscle or nerve cells, as both are mutually
exclusively expressed. The 3.9-kb peri-lacZ expressing cells appear to surround the nerves, suggesting they are Schwann cells. (F and G) In order to verify that
endogenous periostin and the Schwann cell marker Sox10 transcription factor are co-expressed in the dorsal root ganglia, serial sections were probed with 35S-labeled
periostin and 35S-labeled Sox10 in situ probes. While Sox10 is restricted to dorsal root ganglia, sympathetic ganglia and the peripheral nerves; periostin is co-
expressed with Sox10 in the dorsal root ganglia (arrows in panels F and G) and is also present within the aortic arch arteries and OFT endocardial cushion cells (oft).
(H and I) Identical section of an E14 3.9 kb peri-lacZ lacZ-stained embryo was subsequently probed with Sox10 antibody (which marks early Schwann cell precursors).
Note co-expression of 3.9 kb peri-lacZ reporter and nuclear anti-Sox10 fluorescence (arrows in panel I).
344 A. Lindsley et al. / Developmental Biology 307 (2007) 340–355ratios, subsequent analysis and data are derived from line #1 to
ensure consistency.
Reporter 3.9 kb peri-lacZ expression is initially detected at
E10 within the post-migratory pre-Schwann cell precursors.
This makes the 3.9-kb peri enhancer one of the earliest
developmentally regulated Schwann cell promoters to date.
The 3.9-kb peri-lacZ expressing cells radiate out from the
presumptive dorsal root ganglia and encapsulate the developing
peripheral nerves (Fig. 1), including the enteric nerves of the
developing gut, establishing the periostin promoter as a novel
Schwann cell in vivo marker (Fig. 1). Robust reporter
expression in the Schwann cells is maintained throughout
embryogenesis, perinatal development and into adulthood (Fig.
1), indicating that both periostin and 3.9 kb peri enhancer
expression are maintained during transition of the neural crest-
derived precursor into mature Schwann cells. The validity ofFig. 3. 3.9 kb peri-lacZ reporter is also expressed in the developing heart. Developmenta
perilacZ heart (G and H). Isolated lacZ-stained 3.9 kb peri-lacZ whole hearts at E10 (A)
expressing cells. Note speckled expression begins at ∼E10.0 within the OFT and e
positive cells are restricted to the truncal region of the E12 OFT endocardial cushion
OFTand not present in AV region (inset in panel C in rear view of heart shown in pane
the E14 OFT, coincident with completion of OFT septation and interventricular septa
regions of the 3.9-kb peri-lacZ heart shown in panel C. Note that 3.9 kb peri lacZ-posi
absent from the surrounding myocardial cuff and overlying endothelial cells. (F) No 3
(G and H) Whole-mount E12 heterozygous knockin perilacZ hearts stained for lacZ
OFT (large arrow in panel G, heart viewed from front) and the AVendocardial cushi
ventricle; LV=left ventricle; Ao=aortic orifice; P=pulmonary orifice.the reporter expression as well as the identity of the stained
cells was established by marker gene analysis and co-
localization of 3.9 kb peri-lacZ expression with the Schwann
cell marker Sox10 transcription factor (Fig. 2) (Britsch et al.,
2001). Thus, the 3.9-kb peri-lacZ promoter is unable to
completely recapitulate endogenous periostin expression (Fig.
2) but is capable of driving reporter expression within a
subpopulation of endogenously expressing periostin cells. This
is consistent with the hypothesis that modular cis elements
coordinately regulate complex gene expression patterns (Firulli
and Olson, 1997).
In addition to Schwann cell expression, mesenchymal cells
of the cardiac OFT cushions also exhibit 3.9 kb peri-lacZ
expression. At E10, a few individual lacZ-positive cells can
be detected in the truncal region of the OFT (Fig. 3). Coincident
with initiation of mesenchymal condensation and OFTl series of 3.9 kb peri-lacZmouse embryo hearts (A–F) and a heterozygous knockin
, E11 (B), E12 (C) and E14 (D). Black arrows indicate location of 3.9 kb peri-lacZ
xpression increases as development proceeds. (C) Two robust streams of lacZ-
s (indicated by arrows). Also note the 3.9-kb peri-lacZ reporter is restricted to the
l C). (D) The two lacZ-positive streams resolve into a single clump at the base of
l closure. (E and F) Eosin counterstaining of sections through the truncal and AV
tive cells are present in the mesenchymalizing OFT cushion septum (E) but are
.9-kb peri-lacZ lacZ expression is detectable in AV cushions (indicated by arrow).
reveal that endogenous periostin lacZ reporter is robustly expressed in both the
ons (large arrow in panel H, heart viewed from back). Abbreviations: RV=right
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E12 two robust streams of 3.9 kb peri-lacZ expressing cells can be
observed in the aortic and pulmonary conotruncal endocardial
cushions. By E14, these streams have resolved into a small
clump of lacZ-positive cells at the base of the OFT.
Significantly, lacZ staining revealed that the 3.9-kb peri-lacZexpression in the OFT is uniquely restricted (Fig. 3). While
knockin perilacZ, periostin mRNA and protein are all detected
throughout both the proximal and distal OFT and atrioven-
tricular (AV) cushions, 3.9 kb peri-lacZ reporter expression is
restricted to a subpopulation of distal OFT endocardial cushion
cells. This indicates that elements required for AV cushion
346 A. Lindsley et al. / Developmental Biology 307 (2007) 340–355expression are absent from the 3.9-kb promoter and may lie
outside the 3.9-kb domain. Together these data indicate that a
subset of cis-regulatory elements reside within the proximal
4 kb of mouse periostin and that these elements drive
expression in Schwann cells and the cardiac OFT. To further
refine the location of these cis-elements we initiated in vitro
analysis using a Schwannoma cell line.
RT4-D6P2T Schwannoma cell line characterization
While transgenic analysis is unrivaled in its ability to
characterize promoter activity in all of the tissues of a
developing embryo, the technique is not practical for the
systematic identification of smaller regulator modules within a
putative promoter. In contrast, cell culture-based methods have
been highly successful alternatives to exhaustive and expensive
in vivo transgenic analysis. Unfortunately, cell culture
approaches require the availability of cell lines ontologically
appropriate for the expression pattern of the gene of interest.
Given the correlation of aberrant periostin expression in
multiple neoplasias and the robust and sustained 3.9 kbperi-lacZ
reporter expression in the PNS, plus the current lack of
availability of any suitable endocardial cushion cell line, we
used the well characterized RT4-D6P2T (RT4) rat Schwannoma
cell line (Toda et al., 1994; Hai et al., 2002). Schwannomas are
benign nerve sheath tumors composed of abnormally prolifer-Fig. 4. RT4-D6P2T characterization: (A) Western analysis revealed the RT4 Schw
molecular weight secreted periostin isoform, similar to the multiple isoforms express
express two isoforms (∼90 kDa and∼82 kDa) and RT4 supernatant contains secreted
(∼82 kDa) isoform within the cells and do not secrete periostin. Note that there is
specificity. Equal loading was ensured via normalizing for actin levels and loading
shown). (B–D) RT4 cells were grown on uncoated glass culture slides and briefly
hematoxylin nuclear counterstaining. Note cytoplasmic S-100 expression and absenc
(inset in panel B). (C) Anti-Sox10 immunofluorescent staining. Note appropriately l
panel C). (D) Anti-periostin staining, with methyl green nuclear counterstain and D
expression is evident in negative control stained with pre-immune in place of primary
control samples demonstrated that staining was specific. Magnification: all images 4ating Schwann cells. RT4 cells have successfully been used for
the molecular analyses of myelin and other PNS-specific
promoters (Madison et al., 1996; Gonzalez-Martinez et al.,
2003). Prior to molecular dissection of the 3.9-kb periostin
promoter and to verify whether the RT4 cells would be useful
within our system, marker analysis was performed and periostin
expression examined. Western blotting reveals that RT4 cells
normally express periostin and moreover they express both
ECM-bound and secreted isoforms, analogous to those
expressed by mouse in vivo (Fig. 4A). The cell line also proved
to be immunopositive for S-100, a cytoplasmic EF-hand
calcium binding protein (Jessen and Mirsky, 2002) found
predominately in Schwann cells and other glial elements (Fig.
4B). Immunofluorescent detection of the HMG-containing
transcription factor Sox10, a Schwann cell marker (Ye et al.,
1996; Kuhlbrodt et al., 1998; Britsch et al., 2001), revealed a
strong, nuclear localized signal in RT4 cells (Fig. 4C). Finally,
the RT4 cell line is also positive for periostin protein within the
cytoplasm, thus confirming that our gene of interest was
actively expressed by our in vitro model system and therefore
appropriate for promoter analysis (Fig. 4D).
3.9 kb peri deletion analysis
To facilitate the identification of specific regulatory ele-
ments, we cloned the 3.9 kb peri enhancer into the promoterlessannoma cell line, as opposed to NIH3T3 fibroblast line, expresses the higher
ed endogenously in vivo in newborn mice pups. While RT4 cells predominantly
(∼90 kDa) periostin, the NIH3T3 cells only express the lower molecular weight
also a complete absence of periostin in the newborn nulls, verifying antibody
equivalent amounts of supernatant (verified via Coomassie blue staining, not
fixed with 4% PFA prior to immunostaining. (B) Anti S-100 staining, with
e of specific signal in negative control that did not receive the primary antibody
ocalized Sox10 expression in nucleus and same view as phase-contrast (inset in
IC optics. Note expression of periostin localized to the cytoplasm and that no
periostin antibody (inset in panel D). The absence of staining in negative (−ve)
00×.
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internally deleted daughter constructs were all derived from the
pGL2-3.9 kb peri plasmid (Fig. 5). Transfection efficiency was
controlled for by co-transfection of a Renilla luciferase
expression plasmid.
The resulting luciferase reporter data revealed both activat-
ing (α, alpha) and repressing (β, beta) elements within the
periostin proximal promoter (Fig. 5A). Construct A contains the
3.9-kb peri sequence. When compared to cells transfected with
the promoterless pGL2 parent vector, construct A generates a
luciferase activity ∼500-fold stronger, indicating the presence
of the periostin transcriptional start site and putative cis-
elements (data not shown). Deletion of 942 bp from the 5′ prime
end (construct B) results in a 35.3% drop in luciferase activity,
while a more significant 77.7% drop was observed when an
additional 498 bp was removed (construct C). Additional
truncation (constructs D–G) did little to further reduced
luciferase reporter activity, suggesting that the reporter activity
represents the baseline level of transcription from the periostinFig. 5. In vitro analysis of 3.9 kb peri enhancer: (A) Serial and internal truncation of
shown with nucleotide assignment given relative to the transcriptional start site (+
translational start site. (α, alpha) Corresponds to an 804-bp putative enhancer reg
Corresponds to a 477-bp putative repressor region from −1287 to −810 bps upstream
Schematic alignment of the sequences of truncated enhancer-minimal promoter fusion
of six independent transfections (n=6), while error bars represent the standard er
Luminometry results are given in arbitrary units.promoter. Deletion of the putative TATA box further reduced
levels of expression comparable to that observed with pGL2-
Basic vector only, supporting this conclusion (data not shown).
Serial deletion analysis therefore suggested that the most potent
transcriptional activation domains were contained in the most 5′
prime 1.4 kb of the 3.9-kb peri sequences, consistent with our
3.9 kb peri (Fig. 1) and 1.2 kb peri in vivo transgenic data.
We next engineered additional constructs with internal
deletions and assessed resultant reporter activity (constructs
H-J). To further characterize the 5′ prime 1.4-kb element(s), we
first removed an internal DNA fragment from −2119 to −1287.
This construct (construct H) shows an increased luciferase
activity of ∼80% compared to the activity of 3.9 kb peri
(construct A) suggesting the presence of a possible transcrip-
tional repressor element. A similar level of transcriptional
activity was observed when construct H was further truncated
by the removal of its distal 942 bps (construct J); however,
removal of a larger 1637-bp internal fragment (construct I)
reduced luciferase activity to the levels observed with construct3.9 kb peri-pGL2 construct and luminometry results. Schematic of constructs are
1). Sequence includes 18 bp of exon one, up to, but not including the ATG
ion from −2924 to −2119 bps upstream of the transcriptional start. (β, beta)
of the transcriptional start. (B) Dissection of 803 bp peri putative enhancer region.
constructs and intact 3.9 kb peri-pGL2 plasmid. Black bars represent the average
ror. Lysates from each transfection were read twice and the results averaged.
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enhancer within the 804-bp segment of DNA spanning −2924
to −2119 region. A 477-bp internal deletion (construct K), was
also found to significantly increase luciferase activity from that
observed with construct A, suggesting that these sequences may
contribute to the negative regulation of periostin.
In order to further define the putative cis-element, we
designed a set of constructs that isolated the enhancing 804-bp
fragment from other regulatory elements within the full-length
3.9 kb peri while preserving the DNA elements need to drive the
basal transcription. This strategy utilized the minimal promoter
region corresponding to the 423 bps immediately upstream of
the transcriptional start site. The putative 804-bp enhancer
element was fused to the 5′ end of the minimal promoter
element and its transcriptional activity assessed (Fig. 5,
construct iii). An 18.8-fold increase in luciferase reporter
activity is observed. Subsequent truncation of the 804-bp
fragment (constructs iv–vii) results in decreased luciferase
activity. Nevertheless, a moderately enhancing 304-bp core
fragment (−2509 to −2205) was identified within the larger
804-bp fragment, which was sufficient to drive luciferase
expression at a level equivalent to that observed for 3.9 kb peri
promoter. Significantly, sequence identity bioinformatics of the
3.9-kb peri promoter revealed that this 304 bp (−2509 to −2205)
fragment is localized within the region that contains the highest
level of evolutionary conservation (72.94%). Table 1 is a
bioinformatics representation of all known and conserved cis-Table 1
Bioinformatics representation of known and conserved cis-elements within the
304-bp minimal enhancer
Cis-element scan analysis was performed using the MatInspector program,
(Genomatix http://www.genomatix.de/) on the 304-bp peri enhancer contained
within −2509 to −2205 bps of 3.9 kb peri promoter (note necessary 37 bp
fragment is underlined and YY1 elements are indicated via enlarged text). The
optimized matrix threshold was set to minimize false-positive hits, and only the
highest conserved consensus binding sites (each N0.8) are indicated (note: a
perfect match to the matrix scores 1.00, while strong candidates typically show a
similarity of N0.80). The sequence that corresponds to each of the identified cis-
elements is denoted on 304-bp peri enhancer via the color-coded key. An “r”
superscript indicates that the element is in reverse orientation in relation to the
start site. Potential interesting elements identified include several Gata sites and
retinoic acid response elements, an Oct consensus site and pancreatic/intestinal
Lim-homeodomain factor (Isl1) and activator protein-1 (AP-1) sites found
within the 37-bp fragment. Ap-1 has been shown to play a critical role in
Schwann cells differentiation (Miskimins and Miskimins, 2001; Wegner, 2000)
and the myocardialized OFT septum has recently been shown to be derived from
Isl1-expressing cells (Sun et al., 2007).elements within the 304-bp peri minimal enhancer. To further
refine our analysis of these regions, we carefully examined
conserved and aligned sequences within the 304-bp fragment.
Three highly conserved putative transcription factor-binding
sites (highlighted in yellow) were identified and targeted for
additional analysis (Fig. 6A).
Enhancer mutagenesis
Using site-directed mutagenesis, we fused the 804-bp
enhancer to the periostin minimal promoter (construct iii) and
then disrupted the three most highly conserved modules
identified by bioinformatic analysis (Fig. 6B). Mutation of
site 1 and site 2 reduced luciferase activity by ∼80% and
∼65%, respectively, while mutation of site 3 had a minimal
effect (∼17% reduction). Mutation of site 1 reduced luciferase
activity nearly to basal levels, implying that a necessary trans-
activator(s) requires the cis-elements of site 1's sequence in
order to bind and drive transcription. The less dramatic
reduction observed via mutation of site 2 may imply the
binding of factors which moderately enhance periostin's
transcription. Although these data suggest we have further
isolated the cis-elements within the 3.9 kb peri promoter,
validation was required to be sure that these elements function
in vivo.
Transient F0 transgenic analysis
Given the predictions provided by the in vitro analysis of
the promoter, we sought to validate our findings in vivo. Both
the 804-bp and 304-bp putative enhancer elements were
cloned into an Hsp68-lacZ minimal promoter construct and
were used to generate F0 transgenic embryos. At E12.5 (stage
at which 3.9 kb peri reporter expression is maximal in PNS and
OFT), both the Hsp68-804 bp peri-lacZ (n=11) and the Hsp68-
304 bp peri-lacZ (n=6) positive embryos yielded Schwann cell
expression throughout the developing PNS (Fig. 7). Intrigu-
ingly, both constructs yielded embryos that were uniformly
lacZ positive in the mesenchymal cells of the distal OFT
cardiac cushion while only individual, isolated lacZ-positive
cells were observed to sparsely populate the AV cushion (Fig.
7B). Histological analysis revealed that lacZ expression was
restricted to the mesenchyme of the distal OFT cushion, while
the overlying endocardium and surrounding myocardium were
negative (Figs. 7B and C). When compared to the 3.9-kb peri-lacZ
expression pattern (see Fig. 3), the expression patterns ofHsp68-
804 bp peri-lacZ and the Hsp68-304 bp peri-lacZ are both more
extensive in the cardiac cushions, however, they are not ectopic
in nature. As endogenous periostin mRNA and protein
expression can be found throughout the proximal and distal
OFT and AV cushion mesenchyme (Kruzynska-Frejtag et al.,
2001; Lindsley et al., 2005; Litvin et al., 2005), this suggests that
different enhancers may regulate endocardial cushion periostin
expression in different cushions and within different regions of
each cushion. Given the probable repressive element within the
proximal region of 3.9 kb peri, the less restricted expression
patterns of Hsp68-804 bp peri-lacZ and Hsp68-304 bp peri-lacZ
Fig. 6. Bioinformatic analysis of conserved sequences: (A) ClustalW multiple alignment of mouse (−2430 to −2126 bps upstream region), rat, dog and human DNA
sequences. There are three highly significant evolutionary conserved regions of sufficient size to be potential transcription factor binding sites (highlighted in yellow).
Two single-nucleotide polymorphisms (indicated by #) are present in the 304-bp enhancer, one is present within the 37-bp fragment (blue #). (B) All three sites
(designated sites 1, 2 and 3) were targeted for subsequent site-directed mutagenesis. While mutation of site 3 had little effect, mutation of sites 1 and 2 both significantly
reduced luciferase reporter activity in RT4 cells when compared to control 804 bp peri enhancer (n=6). Specifically, mutation of site 1 reduced luciferase to basal levels
(n=6). The less dramatic reduction noted in the mutation of site 2 may imply the binding of factors acting synergistically or with factors that also bind site 1.
349A. Lindsley et al. / Developmental Biology 307 (2007) 340–355may be secondary to the removal of a negative putative
regulatory element.
Protein–DNA interaction analysis
To assess the protein binding capacity of the identified per-
iostin enhancers, 20-bp 32P-radiolabeled double-stranded DNA
probes where generated for sites 1–3 and electromobility shift
assays (EMSAs) were performed. Each probe contained a single
identified site and a minimum of 5 bp of upstream and
downstream flanking sequence. Surprisingly, incubation with
RT4 nuclear extract failed to retard the migration of any of the
individual 20 bp probes (Fig. 8B). In contrast, when a probe
encompassing all three sites (52 bp in total length) was
incubated with the same RT4 nuclear extract, two prominent
shifted bands (complex A, B) and one faint higher shifted band
(complex C) were detected (Fig. 8C). The use of unlabeled
“cold” probe successfully reduced the intensity of all threebands in a dose-proportionate manner whereas a non-specific
DNA sequence of similar length has no such effect. Given that
mutation of site 3 had little effect on promoter luciferase activity
(Fig. 6B), we designed a probe 37 bp in length to examine the
protein-binding capacity of just sites 1 and 2 (Fig. 8D). Results
demonstrate that both the 52-bp (sites 1, 2 and 3) and 37-bp
(sites 1 and 2) EMSA probes are specifically bound by RT4
nuclear extract proteins (whereas single site 20-bp probes did
not) and that they yield a similar distribution of three DNA–
protein complexes, each with discrete migratory properties.
To identify the nucleotides critical for DNA–protein com-
plex formation, we individually mutated sites 1 and 2 within
our 37 bp probe. We found that mutating either site altered
stoichiometry of the three complexes. However, none of the
bands were lost. Mutation of site 1 enhanced the intensity of
the lowest band (complex A), while the faint higher band
became hyper-intense following mutation of site 2 (complex
C). These results suggest either the binding of the proteins that
Fig. 7. Transgenic F0 analysis of periostin enhancer expression. (A) E12.5 whole embryos and isolated hearts stained for lacZ reporter activity. First three panels
illustrate F0 transient transgenic pattern driven by 804 bp
peri enhancer (n=11), while next three panels illustrate F0 304 bp
peri enhancer expression (n=6). Note that the
804-bp peri-lacZ enhancer recapitulates 3.9 kb peri-lacZ PNS (indicated by *) and OFT reporter patterns, and in fact 804 bp peri-lacZ OFT levels may even be enhanced as
lacZ expression is now present within the most of the truncal and conal endocardial cushion cells. However, 304 bp peri-lacZ PNS lacZ expression is markedly reduced
(indicated by *) while OFTexpression is still robust, although restricted to the truncal region. (B) Histological sectioning reveals that 804 bp peri-lacZ reporter expression
is confined to the endocardial cushions within the OFT (arrow). Note that some AV cushion expression is now evident, suggesting loss of repression. (C) Histological
sectioning reveals that 304 bp peri-lacZ expression is also restricted to endocardial cushion cells but is absent in the adjacent myocardial cuff and endothelial cells. Note
304 bp peri-lacZ expression is present in truncal cushions (large arrow in panel C) but is absent in the conal region (small arrow in panel C).
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specific sequence within the probe (i.e. site 2), or binding is
mutually exclusive and factors compete for DNA access. Such
an observation supports the notion that multiple proteins are
cooperatively (perhaps acting synergistically) and/or antago-
nistically binding the probe. As a gel shift was only observed
when the individual 20-bp fragments that failed to bind were
combined, it is more likely that multiple factors bind
cooperatively rather than antagonistically. Thus, each complex
represents the averaged migrational properties of a specific
combination of proteins.
Bioinformatic analysis of the 37-bp fragment identified two
putative YY1 transcription factor consensus binding sites
(Flanagan et al., 1992; Ye et al., 1994; Yarden and Sliwkowski,
2001) overlapping sites 1 and 2. In order to assess the affinity of
RT4 nuclear extract proteins for the YY1 consensus binding
site, a competition assay was performed. A control probe
containing a previously published YY1 consensus site was
labeled and incubated with RT4 nuclear extract and a strong
band was noted that was specific and could be ablated by theaddition of cold YY1 probe (data not shown). When this non-
radiolabeled YY1 control probe was co-incubated with a
radiolabeled 37-bp fragment and RT4 nuclear extract, com-
plexes A-C were significantly reduced in intensity (Fig. 8D,
lane 5) suggesting specific competition. As YY1 and serum
response factor (SRF) are known to be able to compete for
similar binding sites (Lee et al., 1992; Flanagan et al., 1992; Ye
et al., 1994; Yarden and Sliwkowski, 2001), we used an
unlabeled SRF probe to test whether SRF bound the 37-bp
probe. However, co-incubated cold SRF had no significant
effect on complex formation (Fig. 8D, lane 6). These results
suggest proteins that participate in the formation of complexes
A–C also bind the YY1 control probe, but not the SRF control
probe.
To directly test the ability of YY1 to bind the 37-bp probe,
rabbit reticulocyte lysate was used to generate pure recombinant
YY1 protein, both with and without a 3′ prime poly-histone tag.
The identity of the recombinant YY1 was confirmed byWestern
blot (Fig. 8E). When co-incubated with labeled 37-bp probe, a
prominent band was generated, demonstrating that YY1 protein
Fig. 8. Biochemical analysis of 304 bp peri enhancer: (A) Annotated schematic illustrating alignment of various EMSA oligonucleotide probes containing conserved
sites 1, 2 and 3 (highlighted in yellow). Oligo123 is a 52-bp probe containing all three sites of homology. Aligned below are the sequences of Oligo1, Oligo2 and
Oligo3, each represents a 20-bp probe centered on a specific site of homology. Oligo12 is a 37-bp probe containing just sites 1 and 2. Putative YY1 transcription factor
binding sites are aligned below to reveal their inclusion or exclusion within the various probes. (B) 32P-labeled 20 bp double-stranded DNA probes as described above
were hybridized with 3 μg of RT4-derived nuclear extract and cold probe. Note the absence of any bands for all three 20-bp probes, indicating that none of the probes
alone is sufficient to generate DNA–protein complexes. (C) In contrast, when 32P-labeled Oligo123 is co-incubated with the identical nuclear extract, 2 prominent
bands and 1 faint band are generated (denoted as complexes A, B, C). Note that there is a dose-dependent competition of bands with unlabeled cold probe. (D) EMSA
analysis of 37 bp fragment. 32P-radiolabeled 37 bp probe was generated equivalent to Oligo12. Incubation with RT4 nuclear extract resulted in one prominent shifted
band and two faint higher shifted bands (arrowheads, denoted as complexes A, B and C). Note that competition with specific cold competitor abolished all bands, while
non-specific cognate probe had negligible effects. Significantly, given the presence of a YY1 binding site, cold YY1 probe greatly diminished bands while cold SRF
probe had minimal effect. Site-directed mutation of either site 1 or site 2 resulted in alerted stoichiometry/intensity of the bands but did not abolish presence of any
shifted bands (complexes A*, B* and C*). (E) EMSA analysis of 37-bp fragment with YY1-programmed extracts. Pure YY1 protein was generated from pcDNA3-
CMV-YY1 full-length cDNA vector using TnT rabbit reticulocyte lysate expression system (Promega). Unprogrammed lysate failed to retard the migration of the
37-bp probe, while both His-tagged YY1 (slightly larger due to his tag) and YY1 alone resulted in shifted bands. Western blotting with YY1-speific antibody was used
to verify that only the programmed lystate contained YY1 protein.
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YY1's nearly ubiquitous expression, these data support the
notion that YY1 participates in a complex of proteins driving
3.9 kb peri expression patterns.
In vivo site-directed mutagenesis transgenic analysis
Having identified evolutionarily conserved YY1 cis-ele-
ments in the isolated 37-bp element present within the
transcriptionally active Peri304 fragment, we set out to
determine if the 37 bp were specifically necessary for any
part of the observed 3.9-kb peri-lacZ expression. We therefore
deleted the 37-bp from the 3.9-kb peri-lacZ construct and used it
to generate F0 transgenic litters (designated 3900
−37 bp). Our
analysis revealed that deletion of the 37-bp site ablated all in
vivo lacZ reporter expression (n=5/5; Fig. 9). This result
demonstrates that the 37-bp site is a necessary enhancer element
required for 3.9 kb peri expression in the PNS and distal OFT
cardiac cushions and that this sequence contains binding sites
for YY1, implicating it as a regulator of periostin expression inthe Schwann cell and cardiac OFT endocardial cushion cell
lineages.
Discussion
Periostin is normally expressed in a wide spectrum of
embryonic and adult mouse tissues (Kruzynska-Frejtag et al.,
2001; Lindsley et al., 2005) and yet our results demonstrate the
cis-elements which control the vast majority of endogenous
periostin expression do not reside within the immediate 5′
upstream 3.9 kb peri sequence. Instead, we found only a subset
of periostin expression domains are regulated by this ∼4 kb
proximal region, suggesting the existence of additional undis-
covered regulatory elements elsewhere. Bioinformatic analysis
supports this contention by revealing several additional peaks
of identity 3′ of 3.9 kb peri, including intronic regions (data
not shown). While these other homology peaks may harbor
important regulatory elements, caution must be exercised in
attempting to predict which regions are independently capable
of driving transcription based solely on sequence identity.
Fig. 9. Transgenic F0 analysis of periostin 37-bp enhancer requirement. (A)
PCR screening results of Hsp68-3900−37 bp F0 transient transgenic embryos that
each contain the 3.9-kb peri promoter minus the YY1-binding 37 bp fragment.
Five embryos (#s10, 11, 1, 14, 13 placed in copy # order) were obtained, each
of which carried the endogenous periostin promoter (identified as 113 and
219 bp PCR fragments following internal SacII diagnostic digestion) as well as
the Hsp68-3900−37 bp-containing transgenic promoter (identified as a separate
182 bp fragment, upper panel). Note that the intensity of the transgene (182 bp
band) varies, while the endogenous bands are invariant. Although all five
contained the lacZ transgene (verified via subsequent lacZ-specific PCR
screening, lower panel), no β-galactosidase-positive cells could be detected
(even after a weeks X-gal staining at 37 °C). Non-transgenic littermates were
used as negative controls. (B and C) E12.5 whole embryo and isolated Hsp68-
3900−37 bp heart (#10 has highest transgene copy #) stained for lacZ reporter
activity. Note the lack of lacZ reporter activity when the 37-bp internal enhancer
is deleted within the context of the 3.9-kbperi promoter (3900-37 bp; n=5). Thus,
deletion of an internal 37 bp upstream region in the 3.9 kb peri promoter
completely abolishes lacZ reporter activity throughout the entire embryo.
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functional assays can produce misleading data and requires
verification by in vivo experimentation. Thus, generation of
transgenic reporter mouse lines remains the gold standard for
assessing the transcriptional activity of putative enhancer and/or
repressor elements. Our dissection of 3.9 kb peri-lacZ stands as a
case in point. For instance, our in vitro studies proved reliably
predicative for isolating the Schwann cell enhancer module, but
there was no reason to predict the co-capture of the OFT
endocardial cushion enhancer. Similarly, Oshima et al. (2002)
described a putative Twist site (E-box) located 468 bp upstream
of the periostin transcription start that is capable of driving
reporter expression in vitro in mouse MC3T3-E1 osteoblast
cells. Interestingly, we also detect Twist-dependent transactiva-
tion in tissue culture when using various mouse mammary
tumor cell lines (ABF and SJC, unpublished data). Despite the
presence of this conserved E-box in our 3.9 kb peri-lacZ reporter
mice, we were unable to detect lacZ expression in either the
periosteum or cranial suture structures in vivo. While this
identified Twist site may require additional up or downstream
elements to function in vivo, the 3.9-kb peri-lacZ data suggest that
it is unlikely to be involved in in vivo Schwann cell and distal
OFT cushion regulation.Even more striking is the finding of a regulatory element(s)
within the 3.9-kb peri that are active in both cardiac OFT and
Schwann cells, two such seemingly disparate and highly
specific cell populations. This raises questions about possible
links between the transcriptional profiles of these two devel-
opmentally distinct cell types. Interestingly, Schwann cells and
truncal OFT mesenchymal cardiac cushion cells both derive
from neural crest cell precursors that have undergone EMT and
have migrated to new anatomical locations and express YY1.
Significantly, both YY1 and periostin are both amongst a group
of 100 genes identified as being upregulated in the solid tumors
(Pilarsky et al., 2004). Given periostin's upregulation in
numerous neoplasias and its association with tumor metastasis,
transcriptional activation of periostin via the identified PNS/
cardiac-OFT enhancer could be driven by transcription factors
that promote cell motility or migration. This idea is consistent
with periostin's suggested function as a homophilic adhesion
molecule and marker of post-EMT mesenchymal maturation.
Schwann cells and cardiac cushion mesenchyme are also
linked by their dependence on the neuregulin-ErbB signaling
pathway. Targeted deletions of neuregulin-1 (glial growth
factor), ErbB2 and ErbB3 all result in early embryonic lethality
secondary to cardiac malformation while also ablating the vast
majority of developing Schwann cells (Erickson et al., 1997;
Camenisch et al., 2002). Schwann cells and cardiac cushion
mesenchyme also occupy tissue niches with similar ECM
compositions. Hyaluronan, a major component of the cardiac
cushion and myelin sheath ECM, is capable of activating ErbB3
in AV canal explants. Furthermore, AV explants from hyaluro-
nan synthase-2 (Has2) knockout mice, which typically fail to
form cushion mesenchyme, are rescued by the pharmacological
activation of ErbB2 and ErbB3 (Eggli et al., 1992; Spicer et al.,
2002). Unfortunately, Has2 knockout embryos die too early
(E9.0) to assess if they suffer from Schwann cell developmental
defects, but a proposed Has2-conditional knockout mouse
(Spicer et al., 2002) has the potential to address the role of
hyaluronan in Schwann cell development in the near future.
In addition, Schwann and endocardial cushion cells share a
number of molecular markers. Just as Schwann cells express
the EF-hand containing protein S-100, so too do cardiac
fibroblast-like cells, which are densely distributed throughout
the cardiac skeleton, within the four cardiac valves and in the
cardiac chordae tendoneae (Masani et al., 1986). Similarly,
Oki et al. (1995) demonstrated that several glial and Schwann
cell markers in addition to S-100 (glial fibrillary acidic
protein and neurofilament protein) are distributed along the
subendocardial site of developing cardiac valves. Finally, the
Schwann cell marker Sox10 (as well as Sox 8 and 9) is co-
expressed at the sites of endogenous periostin localization
within the developing heart valves and autonomic nerves of
the embryonic heart (Montero et al., 2002). The fact that
Schwann cells and endocardial cushion cells express similar
combinations of proteins, including transcription factors,
suggests that their transcriptional programs overlap, even if
their ultimate phenotypes diverge.
Advances in our understanding of eukaryotic gene
transcription have illuminated how combinations of
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repress gene expression and help to explain how 'ubiquitous'
transcription factors can modulate lineage/tissue-specific gene
programs (Novina and Roy, 1996; Veitia, 2003). Existing as
an enigmatic lynchpin, YY1 is known to be both a
transcriptional repressor and/or activator and has been show
to physically interact with more than a dozen proteins;
including p300, CREB, Hdac2, E1A, FKBP25, C/EBP, c-
myc, B23 and Stat5 (Shia et al., 1997; Bergad et al., 2000;
Inouye and Seto, 1994; Shrivastava and Calame, 1994) that
may cooperatively result in tissue restricted transcriptional
regulation. YY1 is essential for embryonic life with its loss
leading to peri-implantation lethality (Donohoe et al., 1999).
Hundreds of genes may be directly and indirectly regulated
by YY1, although the exact mechanism through which the
factor acts remains unclear in many cases (Inouye and Seto,
1994; Donohoe et al., 1999). Recent data suggested that
YY1 might induce chromatin remodeling in target genes
through the recruitment of histone-modifying enzymes
(Thomas and Seto, 1999). Furthermore, the manipulation of
YY1 gene dosage has also been shown to profoundly alter
global gene expression in the developing embryo (Affar
et al., 2006). With specific regard to the developing cardiac
valves, supportive data are starting to emerge that show
SMAD-mediated modulation of YY1 activity can regulate
BMP responses and cardiac-specific expression of a GATA4/
5/6-dependent Nkx2.5 enhancer (Lee et al., 2004). Thus,
YY1 could be acting as a novel SMAD-interacting protein
that represses SMAD transcriptional activities in a gene-
specific manner and therefore regulates cell differentiation
induced by TGFβ superfamily pathways (Kurisaki et al.,
2003).
This study has defined a novel Schwann cell and distal
OFT cushion-specific enhancer that links the transcriptional
programs of these two divergent lineages and has improved
our understanding of the likely upstream mechanisms that
regulate expression. Understanding how periostin's spatio-
temporal expression pattern is driven is the first step to
facilitating the development of experimental tools essential for
studying the role of periostin in pathological disorders such
as neuromas, nerve tumors and cardiac valve malformations.
Additionally, the 3.9-kb peri promoter can be utilized to drive
tissue-specific expression of Cre recombinase in transgenic
mice, and given the current lack of any cardiac endocardial
cushion-restricted promoters (never mind one that will enable
the molecular characterization of inlet verses outflow cushion
morphogenesis) this may be a useful molecular reagent. Our
analysis has provided potential links between precursor
Schwann cells and OFT endocardial cushion lineages and
also implicated the YY1 protein in post-migratory neural crest
differentiation events. Finally, uncovering the additional
trans-factors and cis-elements that regulate periostin's ex-
pression in these and other tissues is the subject of ongoing
investigations, the results of which will provide greater
insights into the mechanisms by which the tissues of the
developing mammalian embryo so precisely determine their
cell identity and fate.Acknowledgments
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